Topical collections
Tackling Drug Resistance in Ovarian Cancer: Mechanisms, Biomarkers, and Emerging Therapeutics
Open to submissions till 4 March 2026
Microbiome in Reproductive Health, Dysfunction, and Cancer
Open to submissions till 1 July 2025
Nanotechnological Approaches for the Treatment of Ovarian Cancer
Open to submissions till 28 February 2025
Extracellular vesicles
Open to submissions till 30 June 2024
Ongoing collection
COVID-19
Open to submissions
Citation Impact 2023
Journal Impact Factor: 3.8
5-year Journal Impact Factor: 4.2
Source Normalized Impact per Paper (SNIP): 0.957
SCImago Journal Rank (SJR): 0.968
Speed 2024
Submission to first editorial decision (median days): 8
Submission to acceptance (median days): 124
Usage 2024
Downloads: 1,443,643
Altmetric mentions: 320
Editor-in-Chief Dr Ben Tsang has been selected as a 2025 Distinguished Fellow by the Society for the Study of Reproduction (SSR) Awards Committee. Please join us in celebrating this amazing achievement.
A new FDA approved phase I/II clinical trial on recurrent ovarian cancer is now open for enrollment.
Currently recruiting patients at the Brown Cancer Center, University of Louisville, Louisville, KY. UofL. IRB# 22.0392. NCT# 05610735. Please contact: Dr. Whitney Goldsberry or Dr. Sham S. Kakar.
Editor-in-Chief Dr Ben Tsang has been recognised by the Canadian Parliament for significant contributions to science. Please join us in celebrating this amazing achievement.
Editor-in-Chief Dr Sham Kakar has been recognised as being among the top 2% most-cited researchers in the world. Please join us in celebrating this amazing achievement.
Read more here.